Clinical Trials Directory

Trials / Completed

CompletedNCT01490801

Biomarkers in Blood and Tissue Samples From Patients With Epstein-Barr Virus-Positive Hodgkin Lymphoma

Role of the IL-2 Inducible Tcell Kinase in EBV-HLH and EBV+ Hodgkin's Lymphoma

Status
Completed
Phase
Study type
Observational
Enrollment
50 (estimated)
Sponsor
Children's Oncology Group · Network
Sex
All
Age
9 Years
Healthy volunteers
Not accepted

Summary

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research trial studies biomarkers in blood and tissue samples from patients with Epstein-Barr virus positive Hodgkin lymphoma.

Detailed description

OBJECTIVES: * Evaluate germline DNA from patients with Epstein-Barr virus positive (EBV+) and Hodgkin lymphoma (HL) for inducible T-cell kinase (ITK) mutations. * Examine the effects of ITK mutations on expression of the ITK protein. * Determine whether ITK mutations correlate with specific clinical or histopathological features of HL. OUTLINE: Archived blood and tumor tissue samples are analyzed for germline DNA expression and inducible T-cell kinase (ITK) mutations by PCR, IHC, flow cytometry, and western blotting, and EBV-encoded RNA (EBER) using in situ hybridization. Each patient's data, such as date, sex, age, tumor stage and histology at diagnosis, treatment received, response to treatment, development of recurrent disease, date of last follow-up, and outcomes are also collected.

Conditions

Interventions

TypeNameDescription
GENETICDNA analysis
GENETICRNA analysis
GENETICcytogenetic analysis
GENETICin situ hybridization
GENETICmutation analysis
GENETICpolymerase chain reaction
GENETICwestern blotting
OTHERflow cytometry
OTHERimmunohistochemistry staining method
OTHERmedical chart review

Timeline

Start date
2011-12-01
Primary completion
2016-05-01
Completion
2016-05-01
First posted
2011-12-13
Last updated
2016-05-17

Source: ClinicalTrials.gov record NCT01490801. Inclusion in this directory is not an endorsement.